RNLX Renalytix AI Plc - ADR
1,025
$0.6191
$0.0021
(0.34%)
| Watchers | 1,025 |
| 52-Wk Low | $0.2449 |
| 52-Wk High | $4.04 |
| Market Cap | $47.78M |
| Volume | 86,994.00 |
| 52-Wk High | $4.04 |
| 52-Wk Low | $0.2449 |
KidneyIntelX included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)Globe Newswire • 2 months ago
Guidelines highlight the importance of risk prediction and personalized treatment to reduce riskLONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE...
Share to Feed
Regenxbio, Quoin Pharmaceuticals, Renalytix among healthcare movers...
Titoli in rialzo
Il titolo Quoin Pharmaceuticals (NASDAQ:QNRX) salito del 129,59% a 6,36 dollari durante la sessione pre-market di luned .
Le azioni di Renalytix (NASDAQ:RNLX) hanno guadagnato il...
LONDON and SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the Company ), an artificial intelligence-enabled in vitro diagnostics company, focused on...
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 150 points on Thursday.
The Dow traded up 0.42% to 38,585.09 while the NASDAQ fell 0.19% to 15,828.29. The...
Renalytix surges after Medicare draft decision on lead product...
LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the Company ) today announced that the Company will be participating in the upcoming BTIG...
Renalytix Plc (NASDAQ:RNLX Get Free Report) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 672,200 shares, an...
Electronic health record deployment of KidneyIntelX was associated with clinical actions that slowed progression of chronic kidney disease and improved Type 2 diabetes control in just 12 months...